Company / Free Cash Flow per Share
Avalo Therapeutics, Inc. Free Cash Flow per Share History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$2.86
FY2022
5-year range
-$2.86 / -$0.95
FY2018-FY2022
Trend
-201.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow per Share changed -202% YoY in FY2022, a notable deviation from the 5-year average annual change of -142%.
Based on SEC 10-K filings.
-2.86 in FY2022.
Declined from $-0.91 to $-2.86 over the past 2 years.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Avalo Therapeutics, Inc.'s free cash flow per share has declined for 5 consecutive years.
- In FY2022, free cash flow per share decreased 201.7% year-over-year.
- Peak free cash flow per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$2.86 | -201.7% |
| FY2021 | -$0.95 | -3.5% |
| FY2020 | -$0.91 | -92.4% |
| FY2019 | -$0.48 | -302.5% |
| FY2018 | -$0.12 | -108.9% |
| FY2017 | $1.33 | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026